BACKGROUND: Though breast cancer subtype is a key determinant of treatment choice and prognosis, few studies have assessed breast cancer patients' knowledge of estrogen and progesterone receptor (ER/PR) status. METHODS: Women diagnosed with invasive breast cancer at age 18-64 years in 2007 were recruited from the Pennsylvania Cancer Registry, and mailed a questionnaire that asked respondents to identify their ER/PR status. There were 2191 respondents included in the analysis. Agreement between self-report and cancer registry ER/PR status was assessed using kappa statistic. Logistic regression was used to assess the association of demographic, socioeconomic, and tumor factors with inaccurate self-report of ER/PR status. RESULTS: Fifty-nine percent of respondents reported ER/PR positive status, 15% reported ER/PR negative status, 17% responded 'don't know', and 9% did not respond. Overall, there was 69% agreement between self-report and cancer registry data, and fair agreement as measured by kappa (0.36). After excluding women who did not know or did not report their ER/PR status, there was 93% agreement, and substantial agreement as measured by kappa (0.76). Women who were older, non-white, less educated, lower income, and had ER/PR negative disease were significantly more likely to inaccurately report their ER/PR status. CONCLUSIONS: Though a significant proportion of women do not know their hormone receptor status, women who reported their ER/PR status were accurate. Our results suggest room for improvement in patient knowledge of tumor subtypes, but also that self-reported ER/PR status may be a useful surrogate when medical record or cancer registry data is unavailable.
BACKGROUND: Though breast cancer subtype is a key determinant of treatment choice and prognosis, few studies have assessed breast cancerpatients' knowledge of estrogen and progesterone receptor (ER/PR) status. METHODS:Women diagnosed with invasive breast cancer at age 18-64 years in 2007 were recruited from the Pennsylvania Cancer Registry, and mailed a questionnaire that asked respondents to identify their ER/PR status. There were 2191 respondents included in the analysis. Agreement between self-report and cancer registry ER/PR status was assessed using kappa statistic. Logistic regression was used to assess the association of demographic, socioeconomic, and tumor factors with inaccurate self-report of ER/PR status. RESULTS: Fifty-nine percent of respondents reported ER/PR positive status, 15% reported ER/PR negative status, 17% responded 'don't know', and 9% did not respond. Overall, there was 69% agreement between self-report and cancer registry data, and fair agreement as measured by kappa (0.36). After excluding women who did not know or did not report their ER/PR status, there was 93% agreement, and substantial agreement as measured by kappa (0.76). Women who were older, non-white, less educated, lower income, and had ER/PR negative disease were significantly more likely to inaccurately report their ER/PR status. CONCLUSIONS: Though a significant proportion of women do not know their hormone receptor status, women who reported their ER/PR status were accurate. Our results suggest room for improvement in patient knowledge of tumor subtypes, but also that self-reported ER/PR status may be a useful surrogate when medical record or cancer registry data is unavailable.
Authors: Rose C Maly; Yihang Liu; Barbara Leake; Amardeep Thind; Allison L Diamant Journal: Breast Cancer Res Treat Date: 2009-05-16 Impact factor: 4.872
Authors: Renee Royak-Schaler; Lisa D Gardner; Michelle Shardell; Min Zhan; Susan Racine Passmore; Shahinaz M Gadalla; M Katherine Hoy; Katherine H Rak Tkaczuk; Kim Nesbitt Journal: Patient Educ Couns Date: 2009-11-02
Authors: Robin J Bell; Marijana Lijovic; Pam Fradkin; Jo Bradbury; Maria La China; Max Schwarz; Rory Wolfe; Helen Farrugia; Susan R Davis Journal: J Womens Health (Larchmt) Date: 2009-12 Impact factor: 2.681
Authors: Eldin Dzubur; Carine Khalil; Christopher V Almario; Benjamin Noah; Deeba Minhas; Mariko Ishimori; Corey Arnold; Yujin Park; Jonathan Kay; Michael H Weisman; Brennan M R Spiegel Journal: Arthritis Care Res (Hoboken) Date: 2019-02 Impact factor: 4.794
Authors: Heidi S Donovan; Teresa L Hagan; Grace B Campbell; Michelle M Boisen; Leah M Rosenblum; Robert P Edwards; Dana H Bovbjerg; Charles C Horn Journal: Support Care Cancer Date: 2016-01-08 Impact factor: 3.603
Authors: Aimee A D'Aloisio; Hazel B Nichols; M Elizabeth Hodgson; Sandra L Deming-Halverson; Dale P Sandler Journal: BMC Cancer Date: 2017-10-23 Impact factor: 4.430